SILO News & Events

Silo Pharma announced that its board of directors has authorized a share repurchase program to acquire up to $1M of the company's common stock. The company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements. The company had 13,318,273 shares of common stock outstanding as of November 13, 2025, as reported in its quarterly report for the period ended September 30, 2025.

Silo Pharma announced that the Japan Patent Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, a novel intranasal therapeutic targeting Post-Traumatic Stress Disorder, PTSD. The allowed application, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior," strengthens Silo's growing intellectual-property portfolio in stress-modulating therapeutics and supports the Company's strategy to protect its core scientific innovations in key global markets.

Silo Pharma entered into a non-binding Letter of Intent with Allucent to provide clinical research services for two planned Phase 1 studies evaluating its SPC-15 nasal spray in healthy subjects: an Open-Label, Single Ascending Dose study and an Open-Label, Multiple Ascending Dose study. Allucent and Silo intend to negotiate a Master Services Agreement and project-specific Work Order to cover a comprehensive scope of activities across clinical operations, pharmacovigilance, data management, biostatistics, clinical pharmacology modeling & simulation, and medical writing to support execution and reporting of the Phase 1 program. The LOI also outlines proposed payment conditions, including an upfront amount for direct service fees and pass-through costs that would be reconciled against final project invoices.

Silo Pharma announced that it has selected Allucent, a global full-service clinical research organization, CRO, to support the Company's final preparations and planned submission of its investigational new drug application, IND, to the FDA for a Phase 1 clinical trial of its intranasal prophylactic SPC-15 as a treatment for PTSD. The Company currently expects to submit the IND in 2026 and commence its first-in-human, FIH, SPC-15 trial subsequent to FDA approval. Data from an IND-enabling GLP-compliant toxicology and toxicokinetic study, along with findings from a drug-device study of the formulation-specific intranasal spray system used for SPC-15 drug delivery, are expected in early 2026. Silo intends to pursue the FDA's 505(b)(2) accelerated regulatory pathway for clinical development of SPC-15.